



### C. diff. Spores and More Tuesday at 10 AM Pacific November 07th 2017:Encore: Role of the Microbiome in Reducing Risk of C diff Recurrence

Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a phase 3 clinical trial for recurrent Clostridium difficile infection. We will be discussing the role of the Microbiome in reducing the risk of C. diff. infection recurrence.

- [SHARE](#)
- [DOWNLOAD PDF](#)
- [GET CODE](#)

### Tune in

Tuesday at 10 AM Pacific Time on  
VoiceAmerica Health and Wellness  
Channel

- [LISTEN LIVE](#)
- [EPISODE ON DEMAND](#)
- [VIEW HOST PAGE](#)

Questions? Comments?  
Call In Live!  
Toll Free: 1-866-472-5792  
Intl: 001-480-553-5759

### Featured Guest



#### Barbara McGovern MD

Dr. Barbara McGovern is Vice President of Medical Affairs at Seres Therapeutics. She obtained her M.D. degree from the Albert Einstein College of Medicine and did her residency and infectious disease training at Tufts Medical Center where she worked many years as an infectious disease specialist. Dr. McGovern's early clinical career involved working with HIV-infected patients, including the care of incarcerated women with HIV and hepatitis C co-infection. When the rates of morbidity and mortality from HIV declined on potent antiretroviral therapy, she was one of the first to observe that end-stage liver disease secondary to hepatitis C infection had become a leading cause of death in HIV-i

[Read more](#)

### Share This Episode

- [Share On Facebook](#)
- [Share On Twitter](#)
- [Share On LinkedIn](#)

### Connect with VoiceAmerica

Download our mobile apps

